{
    "name": "idursulfase",
    "comment": "Rx",
    "other_names": [
        "Elaprase"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/elaprase-idursulfase-342847",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women; available data from a small number of postmarketing cases in pregnancy are insufficient to inform drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No evidence of adverse effects on pre- and post-natal development observed with twice weekly intravenous administration of drug to pregnant rats from gestation day 6 through lactation day 19 at about 4 times recommended human weekly dose of 0.5 mg/kg based on body surface area"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Anaphylactoid reactions, which may be life threatening, have been observed in some patients during idursulfase infusions",
                "Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria and/or angioedema of throat or tongue have been reported to occur during and after infusions, regardless of duration of the course of treatment",
                "Appropriate medical support should be readily available when idursulfase is administered",
                "Biphasic anaphylactic reactions have also been observed after idursulfase administration, and patients who have experienced anaphylactic reactions may require prolonged observation",
                "Patients with compromised respiratory function or acute respiratory distress may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions and require additional monitoring"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None listed in the manufacturer's label"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of anaphylactoid reactions; monitor patients with compromised respiratory function/acute respiratory disease",
                "Patients with compromised respiratory function or acute febrile or respiratory illness at the time of infusion may be at higher risk of life-threatening complications from hypersensitivity reactions",
                "Risk of hypersensitivity and antibody development is higher in individuals with seere genetic mutations (ie, complete gene deletion, large gene rearrangement, nonsense, frameshift or splice site mutations)",
                "Caution when administering to patients susceptible to fluid overload, or patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function for whom fluid restriction is indicated; risk of serious exacerbation of cardiac or respiratory status during infusions",
                "Development of anti-idursulfase IgG antibodies reported in 51% of patients, which may increase incidence of infusion-related reactions",
                "A registry has been created to track adverse effects, and monitor therapeutic responses during long-term treatment; may contact 1-866-888-0660 or www.eleprase.com"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pyrexia",
            "percent": "63"
        },
        {
            "name": "Headache",
            "percent": "59"
        },
        {
            "name": "Arthralgia",
            "percent": "31"
        },
        {
            "name": "Limb pain",
            "percent": "28"
        },
        {
            "name": "Pruritus",
            "percent": "28"
        },
        {
            "name": "Hypertension",
            "percent": "25"
        },
        {
            "name": "Malaise",
            "percent": "22"
        },
        {
            "name": "Visual disturbance",
            "percent": "22"
        },
        {
            "name": "Wheezing",
            "percent": "19"
        },
        {
            "name": "Abscess",
            "percent": "16"
        },
        {
            "name": "Chest wall musculoskeletal pain",
            "percent": "16"
        },
        {
            "name": "Musculoskeletal dysfunction",
            "percent": "16"
        },
        {
            "name": "Urticaria",
            "percent": "16"
        },
        {
            "name": "AE resulting from injury",
            "percent": "13"
        },
        {
            "name": "Anxiety",
            "percent": "13"
        },
        {
            "name": "Iirritability",
            "percent": "13"
        },
        {
            "name": "Atrial abnormality",
            "percent": "13"
        },
        {
            "name": "Dyspepsia",
            "percent": "13"
        },
        {
            "name": "Infusion site edema",
            "percent": "13"
        },
        {
            "name": "Pruritic rash",
            "percent": "13"
        },
        {
            "name": "Skin disorder",
            "percent": "13"
        },
        {
            "name": "Superficial injury",
            "percent": "13"
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Loss of conaciousness",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "Cardiac arrhythmia",
            "percent": null
        },
        {
            "name": "Cyanosis",
            "percent": null
        }
    ]
}